News >

Venook Highlights Impact of IDEA Trial in Colon Cancer

Danielle Bucco
Published: Monday, Mar 19, 2018

Alan P. Venook, MD

Alan P. Venook, MD
FOLFOX has been the standard chemotherapy regimen for patients with stage III colon cancer, but it can cause peripheral neuropathy in almost every patient, creating a negative impact on quality of life, explains Alan P. Venook, MD.

on Gastrointestinal Cancers, Venook, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discussed the significance of the findings of the international IDEA study investigating doses of FOLFOX for patients with colon cancer.

OncLive: Can you provide some background on the IDEA study and the significance of it?

Venook: The challenge in the management of colon cancer has been our inability to get beyond FOLFOX, which is the chemotherapy that was shown to be helpful in curing more patients in the adjuvant setting back in 2004. The problem with the drug is that it causes peripheral neuropathy in almost every patient. Somewhere between 7 and 8 doses into treatment is the average time of onset neuropathy. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication